Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY: HIMS )

49.28 -17.13 (-25.79%)
Official Closing Price Updated: 7:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
22 23 Next >
MarketBeat Week in Review – 6/3 - 6/7
Equity markets shrugged off a much hotter-than-expected jobs report, but there could be more volatility after the next readings on inflation come out next week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Looking Into Hims & Hers Health's Recent Short Interest
Via Benzinga
EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In May: Where Do Nvidia, Tesla, GameStop, AMC Rank?
Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Looking At Hims & Hers Health's Recent Unusual Options Activity
Via Benzinga
Smart Money Is Betting Big In HIMS Options
Via Benzinga
Unpacking the Latest Options Trading Trends in Hims & Hers Health
Via Benzinga
Kimberly-Clark To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Hims & Hers Health Soars on Generic GLP-1 Rollout Plans
Him & Hers Health Inc. (NYSE: HIMS) provides a direct-to-consumer (DTC) health and wellness platform. The company was best known for prescribing treatments 
Via MarketBeat
Hims & Hers Health Stock Soared This Week: Here's Why
The company is still riding momentum from its recent weight loss drug announcement. 
Via The Motley Fool
SPDR ETF Report For Thursday, May 30
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Thursday, May 30. 
Via Talk Markets
Topics ETFs
Navigating 10 Analyst Ratings For Hims & Hers Health
Via Benzinga
Hims & Hers Is Changing the Game
GLP-1s could be the product that pushes Hims & Hers over the edge to mainstream adoption. 
Via The Motley Fool
Call Option Volumes Spiked For These 3 Stocks
Option traders decided to plow into call contracts for these three stocks, investors can see the specific fundamental reasons behind this decision 
Via MarketBeat
SPDR ETF Report For Wednesday, May 29
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Wednesday, May 29. 
Via Talk Markets
Topics ETFs
SPDR ETF Report For Tuesday, May 28
In this video, Ira Epstein reviews the day's trading in various SPDR-ETF markets for the trading day that ended, Tuesday, May 28. 
Via Talk Markets
Topics ETFs
A New Name in Weight Loss Drugs
Novo Nordisk and Eli Lilly have soared on the popularity of GLP-1 weight loss drugs. Now Hims & Hers is trying to get in on the action with a more available and affordable option. 
Via The Motley Fool
LifeMD Can Surge on Its GLP-1 Offerings
LifeMD is a leading telehealth provider that investors should take note of; the company is entering the GLP-1 market, and its stock could soar as a result 
Via MarketBeat
Soaring Eli Lilly Stock Could Climb Another 24% According to a Wall Street Analyst. Is the Stock a Buy Now?
Plowing $9 billion into a manufacturing facility could help a successful tirzepatide launch reach new heights. 
Via The Motley Fool
The Ultimate Growth Stock to Buy With $20 Right Now
I challenge you to name another $20 stock with more long-term potential. 
Via The Motley Fool
7 Stocks to Dominate in the Next Economic Upturn
Discover the top stocks to buy for the next economic upturn, carefully selected for their robust growth potential. 
Via InvestorPlace
Move Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.
The search for the next GLP-1 drugs that will be blockbuster winners during the next market cycle is on, and here are three contenders. 
Via InvestorPlace
The Growth Stock Shuffle: 2 to Ditch and 1 to Own
Investing in growth stocks requires a keen eye for profitability. Ditch these two unprofitable stocks and embrace this telehealth winner. 
Via InvestorPlace
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day." 
Via Benzinga
Topics ETFs
Meme Stocks GameStop, AMC Fade In Interest After Roaring Kitty Exit: Here's What WallStreetBets Is Eyeing Next
Retail traders could be shifting away from meme stocks to several other stocks seeing strong interest on WallSteetBets. 
Via Benzinga
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
HIMS stock is catching a bid after Hims & Hers announced that it would begin providing access to GLP-1 weight-loss injections. 
Via InvestorPlace
Tech Surge Boosts Nasdaq To Record Highs
The Nasdaq Composite Index is up triple digits and marking new record highs, thanks to rising tech stocks. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Stocks, Gold Reach New Record Highs, Cruise Stocks Rally, GameStop Sinks: What's Driving Markets Monday?
Wall Street rallies on Monday as major US indices reach fresh record highs. Metal commodities surge, Treasury yields stay stable. Cruise stocks soar. 
Via Benzinga
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 14
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.